Order byBest matchMost fresh
MedPage Today22m
Matthew Perry's Doctor Pleads Guilty; CDC Official Resigns; $7.4B Opioid Settlement
Note that some links may require registration or subscription. A physician who supplied Matthew Perry with ketamine prior to the Friends actor's overdose last year will plead guilty to drug charges. ( AP)
CDC Virus Expert Quits With a Scary Warning After RFK Jr.’s Vaccine Panel Purge
A second senior CDC official has resigned in two weeks, citing fears that scientific integrity is being undermined under vaccine sceptic Health and Human Services Secretary Robert F. Kennedy Jr. Dr. Fiona Havers,
Covid-19 and RSV head data scientist dramatically quits saying she doesn’t trust RFK Jr department to use it ‘objectively’
Covid-19 and RSV head data scientist dramatically quits saying she doesn’t trust RFK Jr department to use it ‘objectively’ - Fiona Havers had worked for the Centers of Disease Control for 13 years bef
Moderna falls on doubts over new CDC panel's backing of RSV vaccine
Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group. The mRNA-based RSV shot,
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.
Zacks Investment Research on MSN23h
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine,
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.
Feedback